Stock IDX INTEGRAL DIAGNOSTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Integral Diagnostics Limited

Equities

IDX

AU000000IDX2

Healthcare Facilities & Services

Market Closed - Australian S.E.
Other stock markets
 02:10:53 2024-05-31 am EDT 		5-day change 1st Jan Change
2.44 AUD +3.39% Intraday chart for Integral Diagnostics Limited -0.41% +28.08%
Mar. 06 Morgan Stanley Adjusts Integral Diagnostics’ Price Target to AU$1.85 From AU$1.70, Keeps at Underweight MT
Feb. 21 Jarden Research Adjusts Integral Diagnostics’ Price Target to AU$2.59 From AU$2.54, Keeps at Neutral MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 496.3 759.3 1,033 694.1 764.3 570.8 - -
Enterprise Value (EV) 1 615.4 883.7 1,170 911.9 1,096 805.6 803.7 799.5
P/E ratio 23.8 x 31.1 x 33.3 x 43.9 x 30.9 x -12.2 x 24.2 x 18.6 x
Yield 3.16% 2.44% 2.4% 2.31% 1.83% 2.52% 3.23% 4.06%
Capitalization / Revenue 2.14 x 2.77 x 2.94 x 1.92 x 1.73 x 1.2 x 1.13 x 1.07 x
EV / Revenue 2.65 x 3.22 x 3.33 x 2.53 x 2.49 x 1.7 x 1.6 x 1.5 x
EV / EBITDA 11.6 x 13.8 x 12.5 x 12.2 x 12.9 x 8.85 x 7.77 x 6.99 x
EV / FCF - 15.9 x 23.7 x 97.7 x 40 x 31.6 x 24 x 19.8 x
FCF Yield - 6.3% 4.21% 1.02% 2.5% 3.17% 4.16% 5.05%
Price to Book 3.9 x 3.33 x 4.05 x 2 x 2.05 x 1.83 x 1.79 x 1.73 x
Nbr of stocks (in thousands) 157,066 194,684 198,629 229,071 233,029 233,916 - -
Reference price 2 3.160 3.900 5.200 3.030 3.280 2.440 2.440 2.440
Announcement Date 8/25/19 8/24/20 8/26/21 8/28/22 8/27/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 232.4 274.1 351 361 440.8 475 503.5 533.9
EBITDA 1 53 64.1 93.5 74.8 85.2 91.07 103.5 114.3
EBIT 1 42 49.3 58.59 38.1 43.8 46.58 56.22 65.88
Operating Margin 18.07% 17.99% 16.69% 10.56% 9.94% 9.81% 11.17% 12.34%
Earnings before Tax (EBT) 1 30.62 35.26 45.22 22.56 30.63 -19.09 34.39 45.35
Net income 1 20.98 23 31.27 14.6 25.04 -49.69 23.62 31.86
Net margin 9.03% 8.39% 8.91% 4.05% 5.68% -10.46% 4.69% 5.97%
EPS 2 0.1329 0.1253 0.1560 0.0690 0.1060 -0.2003 0.1008 0.1311
Free Cash Flow 1 - 55.7 49.31 9.33 27.42 25.51 33.45 40.39
FCF margin - 20.32% 14.05% 2.58% 6.22% 5.37% 6.64% 7.57%
FCF Conversion (EBITDA) - 86.9% 52.74% 12.47% 32.19% 28.01% 32.33% 35.34%
FCF Conversion (Net income) - 242.17% 157.71% 63.89% 109.52% - 141.63% 126.76%
Dividend per Share 2 0.1000 0.0950 0.1250 0.0700 0.0600 0.0614 0.0788 0.0992
Announcement Date 8/25/19 8/24/20 8/26/21 8/28/22 8/27/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 131.8 - 170.7 179.1 180.5 179.3 215.7 225.1 231.3 244.6 247.6 265
EBITDA 1 29.3 34.8 52 41.5 39.5 35.3 39.8 45.4 43.2 49.6 50.2 57
EBIT 1 21.94 27.36 35 23.59 22.03 16.07 19.66 24.2 21.2 25.9 27.2 33.7
Operating Margin 16.64% - 20.5% 13.17% 12.2% 8.96% 9.11% 10.75% 9.17% 10.59% 10.99% 12.72%
Earnings before Tax (EBT) 1 - - - 16.39 - - 18.48 12.15 -65.77 16.1 16 23.2
Net income 1 10.9 12.1 19.9 11.37 10.2 4.403 16.14 8.903 -66.8 9.25 11.6 16.7
Net margin 8.27% - 11.66% 6.35% 5.65% 2.46% 7.48% 3.96% -28.88% 3.78% 4.68% 6.3%
EPS 2 - - - 0.0562 - 0.0187 - 0.0375 -0.2862 0.0490 0.0490 0.0710
Dividend per Share 2 0.0550 0.0400 0.0550 0.0700 - 0.0300 0.0250 0.0350 0.0250 0.0350 0.0340 0.0500
Announcement Date 2/19/20 8/24/20 2/21/21 8/26/21 2/22/22 8/28/22 2/16/23 8/27/23 2/19/24 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 119 124 137 218 331 235 233 229
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.246 x 1.941 x 1.47 x 2.912 x 3.888 x 2.578 x 2.251 x 2.002 x
Free Cash Flow 1 - 55.7 49.3 9.33 27.4 25.5 33.5 40.4
ROE (net income / shareholders' equity) 23.2% 17.6% 12.9% 4.85% 6.95% 1.27% 8.08% 10.2%
ROA (Net income/ Total Assets) 10% 6.97% 5.04% 2.03% 3.09% 2.38% 4.56% 5.89%
Assets 1 209.1 330 620.9 719 811 -2,086 517.9 540.7
Book Value Per Share 2 0.8100 1.170 1.280 1.520 1.600 1.340 1.360 1.410
Cash Flow per Share 2 0.2100 0.2900 0.3500 0.1800 0.3000 0.2600 0.3000 0.3400
Capex 1 18.7 26.1 20.3 27.8 44 34.3 37 39
Capex / Sales 8.03% 9.52% 5.77% 7.69% 9.98% 7.22% 7.35% 7.31%
Announcement Date 8/25/19 8/24/20 8/26/21 8/28/22 8/27/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Integral Diagnostics Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
2.44 AUD
Average target price
2.54 AUD
Spread / Average Target
+4.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
INTEGRAL DIAGNOSTICS LIMITED Stock Integral Diagnostics Limited
+28.08% 367M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-24.16% 7.66B
RADNET, INC. Stock RadNet, Inc.
+68.65% 4.35B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
+2.72% 2.62B
SYNLAB AG Stock SYNLAB AG
-2.98% 2.53B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-46.17% 2.21B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-15.27% 1.79B
FLEURY S.A. Stock Fleury S.A.
-22.12% 1.48B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+13.62% 1.18B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-43.81% 1.13B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. IDX Stock
  4. Financials Integral Diagnostics Limited